Diagnostic and prognostic impact of cytokeratin 19 expression analysis in human tumors: a tissue microarray study of 13,172 tumors
Standard
Diagnostic and prognostic impact of cytokeratin 19 expression analysis in human tumors: a tissue microarray study of 13,172 tumors. / Menz, Anne; Bauer, Rifka; Kluth, Martina; Marie von Bargen, Clara; Gorbokon, Natalia; Viehweger, Florian; Lennartz, Maximilian; Völkl, Cosima; Fraune, Christoph; Uhlig, Ria; Hube-Magg, Claudia; De Wispelaere, Noémi; Minner, Sarah; Sauter, Guido; Kind, Simon; Simon, Ronald; Burandt, Eike; Clauditz, Till; Lebok, Patrick; Jacobsen, Frank; Steurer, Stefan; Wilczak, Waldemar; Krech, Till; Marx, Andreas H; Bernreuther, Christian.
in: HUM PATHOL, Jahrgang 115, 09.2021, S. 19-36.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Diagnostic and prognostic impact of cytokeratin 19 expression analysis in human tumors: a tissue microarray study of 13,172 tumors
AU - Menz, Anne
AU - Bauer, Rifka
AU - Kluth, Martina
AU - Marie von Bargen, Clara
AU - Gorbokon, Natalia
AU - Viehweger, Florian
AU - Lennartz, Maximilian
AU - Völkl, Cosima
AU - Fraune, Christoph
AU - Uhlig, Ria
AU - Hube-Magg, Claudia
AU - De Wispelaere, Noémi
AU - Minner, Sarah
AU - Sauter, Guido
AU - Kind, Simon
AU - Simon, Ronald
AU - Burandt, Eike
AU - Clauditz, Till
AU - Lebok, Patrick
AU - Jacobsen, Frank
AU - Steurer, Stefan
AU - Wilczak, Waldemar
AU - Krech, Till
AU - Marx, Andreas H
AU - Bernreuther, Christian
N1 - Copyright © 2021 Elsevier Inc. All rights reserved.
PY - 2021/9
Y1 - 2021/9
N2 - To evaluate cytokeratin 19 (CK19) expression in normal and cancerous tissues, 15,977 samples from 122 tumor types and 608 samples of 76 normal tissue types were analyzed by immunohistochemistry (IHC). In normal tissues, CK19 expression occurred in epithelial cells of most glandular organs but was strictly limited to the basal cell layer of nonkeratinizing squamous epithelium and absent in the skin. CK19 expression in ≥90% of cases was seen in 34% of the tumor entities including the adenocarcinomas of the pancreas (99.4%), colorectum (99.8%), esophagus (98.7%), and stomach (97.7%), as well as breast cancer (90.0%-100%), high-grade serous (99.1%) or endometrioid (97.8%) ovarian cancer, and urothelial carcinoma (92.6%-100%). A low CK19 positivity rate (0.1-10%) was seen in 5 of 122 tumor entities including hepatocellular carcinoma and seminoma. A comparison of tumor versus normal tissue findings demonstrated that upregulation and downregulation of CK19 can occur in cancer and that both alterations can be linked to unfavorable phenotypes. CK19 downregulation was linked to high grade (p = 0.0017) and loss of estrogen receptor- and progesterone receptor-expression (p < 0.0001 each) in invasive breast carcinoma of no special type. CK19 upregulation was linked to nodal metastases in neuroendocrine tumors and papillary thyroid carcinomas (p < 0.05 each) and to poor grade in clear cell renal cell carcinoma (p < 0.05). CK19 upregulation was particularly common in squamous cell carcinomas. We concluded that CK19 IHC might separate primary liver cell carcinoma from liver metastases, seminoma from other testicular tumors, and helps in the detection of early neoplastic transformation in squamous epithelium.
AB - To evaluate cytokeratin 19 (CK19) expression in normal and cancerous tissues, 15,977 samples from 122 tumor types and 608 samples of 76 normal tissue types were analyzed by immunohistochemistry (IHC). In normal tissues, CK19 expression occurred in epithelial cells of most glandular organs but was strictly limited to the basal cell layer of nonkeratinizing squamous epithelium and absent in the skin. CK19 expression in ≥90% of cases was seen in 34% of the tumor entities including the adenocarcinomas of the pancreas (99.4%), colorectum (99.8%), esophagus (98.7%), and stomach (97.7%), as well as breast cancer (90.0%-100%), high-grade serous (99.1%) or endometrioid (97.8%) ovarian cancer, and urothelial carcinoma (92.6%-100%). A low CK19 positivity rate (0.1-10%) was seen in 5 of 122 tumor entities including hepatocellular carcinoma and seminoma. A comparison of tumor versus normal tissue findings demonstrated that upregulation and downregulation of CK19 can occur in cancer and that both alterations can be linked to unfavorable phenotypes. CK19 downregulation was linked to high grade (p = 0.0017) and loss of estrogen receptor- and progesterone receptor-expression (p < 0.0001 each) in invasive breast carcinoma of no special type. CK19 upregulation was linked to nodal metastases in neuroendocrine tumors and papillary thyroid carcinomas (p < 0.05 each) and to poor grade in clear cell renal cell carcinoma (p < 0.05). CK19 upregulation was particularly common in squamous cell carcinomas. We concluded that CK19 IHC might separate primary liver cell carcinoma from liver metastases, seminoma from other testicular tumors, and helps in the detection of early neoplastic transformation in squamous epithelium.
U2 - 10.1016/j.humpath.2021.05.012
DO - 10.1016/j.humpath.2021.05.012
M3 - SCORING: Journal article
C2 - 34102222
VL - 115
SP - 19
EP - 36
JO - HUM PATHOL
JF - HUM PATHOL
SN - 0046-8177
ER -
